Results 31 to 40 of about 29,549 (204)
npj Precision Oncology, 2023 Patients with ROS1-rearranged NSCLC demonstrate excellent disease control with ROS1-targeted therapy, but acquired resistance is inevitable. Of particular interest is the ROS1 L2086F kinase domain mutation which is refractory to all currently available ...
Mandy Sakamoto, Tejas Patil
doaj +1 more source
Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia. [PDF]
, 2016 High hyperdiploidy (HD), the most common cytogenetic subtype of B-cell acute lymphoblastic leukemia (B-ALL), is largely curable but significant treatment-related morbidity warrants investigating the biology and identifying novel drug targets.
de Smith, Adam J +10 more
core +1 more source
Scientific Reports, 2017 ROS1 rearrangement is observed in 1–2% of non-small cell lung cancers (NSCLC). The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has induced marked tumour shrinkage in ROS1-rearranged cancers.
Hayato Ogura +5 more
doaj +1 more source
Progress of non-small-cell lung cancer with ROS1 rearrangement
Frontiers in Molecular Biosciences, 2023 ROS1 rearrangement is found in 0.9%–2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge
Xin Yang +4 more
doaj +1 more source
Targeted DNA demethylation of the Arabidopsis genome using the human TET1 catalytic domain. [PDF]
, 2018 DNA methylation is an important epigenetic modification involved in gene regulation and transposable element silencing. Changes in DNA methylation can be heritable and, thus, can lead to the formation of stable epialleles. A well-characterized example of
Gallego-Bartolomé, Javier +8 more
core +2 more sources
Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]
, 2018 Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma +7 more
core +2 more sources
A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features. [PDF]
PLoS ONE, 2016 AIMS:To identify the clinical and histological characteristics of ROS1-rearranged non-small-cell lung carcinomas (NSCLCs) and build a prediction model to prescreen suitable patients for molecular testing.
Jianya Zhou +8 more
doaj +1 more source
DDM1 and ROS1 have a role in UV-B induced- and oxidative DNA damage in A. thaliana [PDF]
, 2013 Absorption of UV-B by DNA induces the formation of covalent bonds between adjacent pyrimidines. In maize and arabidopsis, plants deficient in chromatin remodeling show increased DNA damage compared to WT plants after a UV-B treatment.
Casati, Paula +2 more
core +3 more sources
CHRISMED Journal of Health and ResearchBackground: Lung cancer is a leading cause of cancer-related mortality, and nonsmall-cell lung carcinoma (NSCLC) accounts for around 85% of lung cancer cases.
Gurpreet Kaur Walia +2 more
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2018 Objective To construct the recombinant plasmid carrying CD74-ROS1 fusion gene, and explore its effect on migration ability of A549 cells. Methods CD74 and ROS1 genes were obtained through PCR. The CD74-ROS1 fusion gene was constructed by fusion PCR.
WU Yazhou, LI Jia, ZHANG Lei
doaj +1 more source